Last reviewed · How we verify
Fibrogammin P
At a glance
| Generic name | Fibrogammin P |
|---|---|
| Sponsor | Children's Hospital of Orange County |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of Factor XIII (FXIII) Concentrate (NA)
- CSL Behring Sclero XIII (PHASE2)
- RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma (PHASE3)
- An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency (PHASE3)
- A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency (PHASE3)
- A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fibrogammin P CI brief — competitive landscape report
- Fibrogammin P updates RSS · CI watch RSS
- Children's Hospital of Orange County portfolio CI